Biotech Paradox: Acrivon's Clinical Win Fails to Impress Wall Street as ACRV Tumbles 29%

Acrivon Therapeutics, Inc. (ACRV) experienced a sharp market correction on Nasdaq, with shares tumbling 28.71% to settle at $2.1044 following the unveiling of Phase 2b interim trial results for its experimental endometrial cancer treatment ACR-368. Despite unveiling what the company characterized as encouraging efficacy data, investor sentiment turned decidedly negative.

The clinical milestone revealed noteworthy response metrics in the serous endometrial cancer population: a 52 percent confirmed overall response rate among patients with a limited treatment history (two or fewer prior therapy lines), alongside a more robust 67 percent response rate among biomarker-positive cohorts. These figures suggested the candidate’s therapeutic potential in a difficult-to-treat malignancy. Yet the data failed to sustain investor confidence, creating a puzzling disconnect between clinical promise and market valuation.

The intraday trading activity painted a volatile picture. Acrivon opened the session near $2.95, fell to a low of approximately $1.98, and briefly recovered to nearly $3.12 before settling lower. The disparity between the opening price of $2.95 and closing price of $2.1044 underscored investor hesitation. Trading volume surged significantly above historical daily averages, indicating substantial portfolio rebalancing as market participants reassessed their positions.

The apparent contradiction between positive trial outcomes and negative price action may reflect investor skepticism regarding trial design, commercial viability, competitive landscape, or broader biotech sector headwinds. Acrivon announced plans to expand the Phase 2b trial into European Union markets, aimed at accelerating patient enrollment and potentially strengthening the evidence base for regulatory submissions.

The company’s 52-week trading range—spanning from approximately $1.05 to $8.00—underscores the substantial volatility characterizing biotech equities, where clinical readouts and trial progression dominate price dynamics far more than traditional sectors.